Core Insights - Rhythm Pharmaceuticals announced positive data from its Phase 3 TRANSCEND trial for setmelanotide in patients with acquired hypothalamic obesity, indicating potential for the drug to be the first approved therapy for this condition [1][2] Group 1: Trial Data and Efficacy - The 52-week data from the trial showed a placebo-adjusted difference in BMI reduction of -18.8% across all patients (N=142), with a mean BMI reduction of -16.4% for those on setmelanotide compared to a +2.4% increase for placebo [5][6] - Among patients aged 12 and older (n=98), the setmelanotide group experienced an average weekly reduction of 2.5 points in hunger scores, compared to a 1.3-point reduction in the placebo group [6] Group 2: Regulatory Status - Rhythm's supplemental New Drug Application (sNDA) for setmelanotide is under review by the U.S. FDA, with a PDUFA goal date set for March 20, 2026 [2][5] - The European Medicines Agency (EMA) is reviewing a Type II variation submission for the Marketing Authorization Application (MAA) for the same indication, with an opinion expected in Q2 2026 [3] Group 3: Market Potential - Rhythm estimates there are approximately 10,000 patients with acquired hypothalamic obesity in the U.S., 10,000 in Europe, and between 5,000 to 8,000 in Japan [4] - The company is preparing to submit a full data package to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for marketing authorization [3]

Core Insights - Rhythm Pharmaceuticals announced positive data from the Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity, showing an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks [1][5] - The company aims to become the first to receive FDA approval for a therapy targeting acquired hypothalamic obesity, with a PDUFA goal date set for March 20, 2026 [2][3] Company Overview - Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product, setmelanotide, designed to treat hyperphagia and severe obesity [6][8] - The company has received FDA approval for setmelanotide to reduce excess body weight in patients with specific genetic obesity syndromes [7][8] Clinical Trial Data - The TRANSCEND trial met its primary endpoint with a mean BMI reduction of 16.4% from baseline for patients on setmelanotide compared to a 2.4% increase for placebo [5] - Among patients aged 12 and older, the setmelanotide group showed a significant reduction in hunger scores, averaging a 2.5-point decrease compared to 1.3 points in the placebo group [5] Regulatory Pathways - Rhythm is in the process of submitting a supplemental New Drug Application (sNDA) to the FDA, with a final data package submission scheduled for March 2, 2026 [2][3] - The European Medicines Agency (EMA) is reviewing a Type II variation submission for setmelanotide, with an opinion expected in Q2 2026 [3] Market Potential - The estimated patient population for acquired hypothalamic obesity includes approximately 10,000 patients in the U.S., 10,000 in Europe, and between 5,000 to 8,000 in Japan [4]

Core Viewpoint - Rhythm Pharmaceuticals is set to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS) during a live conference call on December 11, 2025 [1] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with specific genetic obesity syndromes [4][5] - Setmelanotide is also authorized by the European Commission and the UK's Medicines & Healthcare Products Regulatory Agency for similar indications [4][6] - Rhythm is advancing a clinical development program for setmelanotide in other rare diseases and is exploring investigational MC4R agonists and small molecules for congenital hyperinsulinism [4] Conference Call Details - The live conference call and webcast will take place at 8:00 a.m. ET on December 11, 2025, with participants encouraged to join ten minutes early [2] - A webcast of the call will be available on the Rhythm Pharmaceuticals website and archived for 30 days [3] Indications and Usage - In the U.S., setmelanotide is indicated for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS), POMC, PCSK1, or LEPR deficiency [5] - In the EU and UK, it is indicated for obesity and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1 and LEPR deficiencies [6] Limitations and Contraindications - Setmelanotide is not indicated for patients with benign or likely benign variants of POMC, PCSK1, or LEPR deficiency, nor for other types of obesity unrelated to these conditions [7][8] Warnings and Precautions - Adverse reactions include skin hyperpigmentation, sexual arousal disturbances, and potential for depression and suicidal ideation [9][10][11] - Serious hypersensitivity reactions have been reported, necessitating caution in prescribing [12] Adverse Reactions - Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection [15]

Core Insights - Rhythm Pharmaceuticals has received acceptance for its supplemental New Drug Application (sNDA) for setmelanotide from the U.S. FDA, with a PDUFA goal date set for December 20, 2025, indicating a priority review status [1] - The European Medicines Agency (EMA) has also validated a Type II variation submission for setmelanotide for the treatment of acquired hypothalamic obesity, with the review process initiated on August 16, 2025 [2] - Setmelanotide is already approved for other obesity-related conditions and is a melanocortin-4 receptor (MC4R) agonist, highlighting its potential in treating rare neuroendocrine diseases [3] Company Developments - Rhythm Pharmaceuticals will host an event titled "Commercial Readiness for Acquired Hypothalamic Obesity" on September 24, 2025, to discuss U.S. launch plans and the urgent need for treatment in this patient population [5] - The company emphasizes its commitment to expediting the availability of setmelanotide for patients suffering from acquired hypothalamic obesity, which presents unique challenges compared to general obesity [4] Clinical Trial Insights - The pivotal Phase 3 TRANSCEND trial involved 120 patients and demonstrated a statistically significant -19.8% placebo-adjusted reduction in body mass index (BMI) after 52 weeks of treatment with setmelanotide [4] - In the TRANSCEND trial, participants on setmelanotide achieved a -16.5% reduction in mean BMI compared to a +3.3% increase in the placebo group, with significant results across both adult and pediatric populations [4] Market Potential - Rhythm estimates that there are between 5,000 to 10,000 individuals in the U.S. and 3,500 to 10,000 in the EU living with acquired hypothalamic obesity, indicating a targeted market for setmelanotide [10]

Core Insights - Rhythm Pharmaceuticals presented new real-world data demonstrating that setmelanotide leads to significant weight reduction in patients with acquired or congenital hypothalamic obesity [1][3][10] Group 1: Clinical Data Presentation - New data was presented at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology, and the 32nd annual European Congress on Obesity, showcasing the effectiveness of setmelanotide [1][2] - The presentations included data from 35 patients treated with setmelanotide for up to nine months, showing consistent improvements in body mass index (BMI), BMI-z, and hunger scores [1][4] Group 2: Patient Outcomes - Among adult patients with acquired hypothalamic obesity, there was a mean BMI reduction of -11.9% at three months, -19.2% at six months, and -23.0% at nine months [5] - Pediatric patients also showed a decrease in BMI z-scores, with a mean reduction of 0.3 at three months and 0.4 at both six and nine months [5][11] Group 3: Safety Profile - Setmelanotide was generally well tolerated, with common adverse events including injection site reactions and skin hyperpigmentation, consistent with its established safety profile [6][10] Group 4: Future Developments - Rhythm Pharmaceuticals plans to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency for setmelanotide in the third quarter of 2025 [10]